Multicenter evaluation of rapid antimicrobial susceptibility testing by VITEK®2 directly from positive blood culture

Diagn Microbiol Infect Dis. 2023 Jul;106(3):115950. doi: 10.1016/j.diagmicrobio.2023.115950. Epub 2023 Apr 5.

Abstract

Study objective: To compare the antimicrobial susceptibility testing (AST) performance of positive blood cultures (PBC) VITEK®2 off-label use (D0) and traditional VITEK®2 workflow using isolated colonies after overnight (D1).

Methods: Patient samples with monomicrobial Gram-negative rod or Gram-positive cocci in clusters bacteremia were tested on D0 and compared to D1 AST results in 7 laboratories in France.

Results: Overall, categorical and essential agreement rates were 98.4% and 96.7%, respectively. Very major discrepancy and major discrepancy rates for Enterobacterales and Staphylococci satisfied the NF EN ISO 20776-2 (2007) criteria for sepsis-relevant drugs. Very major discrepancies were >3% for amoxicillin-clavulanate (4.9%, 6/122), piperacillin-tazobactam (7.5%, 4/53) and meropenem (33%,1/3) for Enterobacterales and gentamicin for Staphylococci (4.6%, 4/87).

Conclusion: Direct AST from PBC broths by VITEK®2 for Enterobacterales and Staphylococci is reliable and fast and may positively influence antimicrobial stewardship.

Keywords: blood culture; blood culture broth; bloodstream infection; rapid antibiotic susceptibility testing.

Publication types

  • Multicenter Study

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacteremia* / diagnosis
  • Blood Culture / methods
  • Gammaproteobacteria*
  • Gram-Negative Bacteria
  • Gram-Negative Bacterial Infections*
  • Humans
  • Microbial Sensitivity Tests
  • Staphylococcus

Substances

  • Anti-Bacterial Agents